Mary Anne Heino Sells 10,064 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) Stock

Lantheus Holdings, Inc. (NASDAQ:LNTH – Get Rating) CEO Mary Anne Heino sold 10,064 shares of the firm’s stock in a transaction dated Wednesday, March 8th. The stock was sold at an average price of $74.70, for a total value of $751,780.80. Following the sale, the chief executive officer now directly owns 719,397 shares in the company, valued at approximately $53,738,955.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Mary Anne Heino also recently made the following trade(s):

• On Monday, March 6th, Mary Anne Heino sold 12,189 shares of Lantheus stock. The shares were sold at an average price of $73.24, for a total value of $892,722.36.
• On Friday, March 3rd, Mary Anne Heino sold 82,055 shares of Lantheus stock. The shares were sold at an average price of $73.00, for a total value of $5,990,015.00.

Lantheus Stock Down 2.6 %

LNTH stock opened at $71.26 on Friday. The company has a quick ratio of 2.59, a current ratio of 2.74 and a debt-to-equity ratio of 1.25. The business has a 50 day moving average price of $59.64 and a two-hundred day moving average price of $64.07. The company has a market cap of $4.81 billion, a price-to-earnings ratio of 209.59 and a beta of 0.64. Lantheus Holdings, Inc. has a twelve month low of $47.46 and a twelve month high of $87.47.

Lantheus (NASDAQ:LNTH – Get Rating) last posted its quarterly earnings results on Thursday, February 23rd. The medical equipment provider reported $1.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.87 by $0.41. Lantheus had a return on equity of 51.60% and a net margin of 3.00%. The firm had revenue of $263.17 million during the quarter, compared to the consensus estimate of $244.61 million. Analysts anticipate that Lantheus Holdings, Inc. will post 4.46 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. CWM LLC boosted its stake in shares of Lantheus by 82.1% during the 3rd quarter. CWM LLC now owns 366 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 165 shares during the period. Wipfli Financial Advisors LLC bought a new position in shares of Lantheus during the 3rd quarter worth approximately $30,000. Wolverine Asset Management LLC bought a new position in shares of Lantheus during the 4th quarter worth approximately $36,000. Focused Wealth Management Inc bought a new position in shares of Lantheus during the 3rd quarter worth approximately $63,000. Finally, Coppell Advisory Solutions Corp. bought a new position in shares of Lantheus during the 4th quarter worth approximately $48,000. 97.62% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. JMP Securities assumed coverage on Lantheus in a research report on Wednesday. They issued an “outperform” rating and a $120.00 target price on the stock. Mizuho lifted their target price on Lantheus from $105.00 to $115.00 and gave the company a “buy” rating in a research report on Friday, February 24th. StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a research report on Monday, February 27th. Finally, SVB Leerink assumed coverage on Lantheus in a research report on Wednesday, November 30th. They issued an “outperform” rating on the stock. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, Lantheus presently has an average rating of “Moderate Buy” and an average price target of $107.33.

Lantheus Company Profile

(Get Rating)

Lantheus Holdings, Inc engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments.